Question explored with the scientific record
CCSVI success of angioplasty
The short version: in the only sham-controlled trials, opening those neck veins did not improve MS, and some patients did worse on MRI.
The controlled evidence is negative. A review of four randomized trials found no consistent clinical benefit from venous angioplasty for CCSVI in MS [1]. In one double-blind, sham-controlled trial, 5 of 9 treated patients showed increased disease activity on MRI versus 2 of 10 in the sham group, and some sham patients reported feeling better [3]. That last detail matters: subjective improvement shows up even when the vein was never really opened.
The positive numbers come from uncontrolled studies, where hope and placebo do the work. A four-year follow-up of 366 patients found fatigue "improvement" in 98.5% of relapsing-remitting patients, but there was no untreated comparison group and patients chose their own doctor [6]. A YouTube analysis found 86% self-reported improvement, with mobility actually improving in only 18% [4]. A retrospective series reported 54% symptomatic improvement, again with no control [5].
| Study type | Design | Result |
|---|---|---|
| Sham-controlled trial | Treated vs fake procedure | No clinical benefit; more MRI activity in treated [3] |
| Four RCT review | Pooled randomized | No consistent efficacy [1] |
| 4-year follow-up | No control group | 98.5% fatigue "improvement" [6] |
| YouTube self-report | Self-selected videos | 86% any improvement, 18% mobility [4] |
"Success" in the positive studies means the patient says they feel better, or the vein looks open on ultrasound. Neither is a hard outcome. Patency was 53% in jugular veins at 18 months [2]. Seven progressive patients developed jugular thrombosis after a second procedure [6].
My call: for MS outcomes, angioplasty for CCSVI is not worth it; the sham-controlled data show no benefit and a signal of more MRI disease activity. Confidence: moderate.
Sources used 6
-
An overview of randomized controlled trials on endovascular treatment for chronic cerebrospinal venous insufficiency in multiple sclerosis patients
A narrative overview of four RCTs found no consistent clinical efficacy of venous angioplasty for CCSVI in multiple sclerosis, though selected MRI/subgroup benefits and rare serious adverse events warrant targeted trials.
DOI: 10.1055/a-1061-3205 -
The chronic cerebrospinal venous insufficiency syndrome
This narrative review argues that CCSVI, marked by extracranial venous stenoses, is associated with MS and may be treated by balloon angioplasty, though controlled evidence remains limited.
DOI: 10.1258/phleb.2010.009083 -
Venous angioplasty for “CCSVI” in multiple sclerosis
An editorial assessing the randomized, double-blind, sham-controlled trial of venous angioplasty for CCSVI in multiple sclerosis, concluding no clinical benefit and possible increased disease activity on MRI, and arguing against further trials or use of the procedure.
DOI: 10.1212/WNL.0000000000000651 -
Social Media Representation of Chronic Cerebrospinal Venous Insufficiency Intervention for Multiple Sclerosis
YouTube content about CCSVI angioplasty for multiple sclerosis was predominantly favorable: 86% of 224 people with MS reported symptom improvement, and most health-care professional videos were positive, though mobility improvement was limited and scientific evidence was lacking.
DOI: 10.7224/1537-2073.2014-073 -
Abstract No. 47: High pressure balloon angioplasty to treat internal jugular vein stenoses in patients with CCSVI
Conference abstracts report that intravascular ultrasound (IVUS) improves detection and treatment of venous lesions in CCSVI, with high-pressure angioplasty showing short-term quality-of-life benefits and a 54% symptomatic improvement rate.
DOI: 10.1016/j.jvir.2011.12.083 -
May symptoms of chronic cerebrospinal venous insufficiency be improved by venous angioplasty? An independent 4-year follow up on 366 cases
In an uncontrolled four-year follow-up of 366 multiple sclerosis patients with CCSVI, venous angioplasty was followed by sustained symptom improvement mainly in relapsing-remitting disease, while progressive patients often improved briefly and then relapsed.
DOI: 10.4081/vl.2015.5400